BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35293077)

  • 1. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype.
    Takei R; Brown KK; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Suzuki A; Furukawa T; Fukuoka J; Johkoh T; Goto Y; Kondoh Y
    Respirology; 2022 May; 27(5):333-340. PubMed ID: 35293077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive fibrosing interstitial lung disease: prevalence and clinical outcome.
    Kwon BS; Choe J; Chae EJ; Hwang HS; Kim YG; Song JW
    Respir Res; 2021 Oct; 22(1):282. PubMed ID: 34719401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases.
    Salonen J; Purokivi M; Bloigu R; Kaarteenaho R
    BMJ Open Respir Res; 2020 Apr; 7(1):. PubMed ID: 32265195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute exacerbations of fibrotic interstitial lung diseases.
    Suzuki A; Kondoh Y; Brown KK; Johkoh T; Kataoka K; Fukuoka J; Kimura T; Matsuda T; Yokoyama T; Fukihara J; Ando M; Tanaka T; Hashimoto N; Sakamoto K; Hasegawa Y
    Respirology; 2020 May; 25(5):525-534. PubMed ID: 31426125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
    Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
    Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study.
    Cao M; Sheng J; Qiu X; Wang D; Wang D; Wang Y; Xiao Y; Cai H
    BMC Pulm Med; 2019 Nov; 19(1):215. PubMed ID: 31727051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reticulation pattern without honeycombing on high-resolution CT is associated with the risk of disease progression in interstitial lung diseases.
    Mononen M; Saari E; Hasala H; Kettunen HP; Suoranta S; Nurmi H; Kärkkäinen M; Selander T; Randell J; Laurikka J; Uibu T; Koskela H; Kaarteenaho R; Purokivi M
    BMC Pulm Med; 2022 Aug; 22(1):313. PubMed ID: 35965320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases.
    Adegunsoye A; Oldham JM; Bellam SK; Montner S; Churpek MM; Noth I; Vij R; Strek ME; Chung JH
    Ann Am Thorac Soc; 2019 May; 16(5):580-588. PubMed ID: 30653927
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease.
    Niitsu T; Fukushima K; Komukai S; Takata S; Abe Y; Nii T; Kuge T; Iwakoshi S; Shiroyama T; Miyake K; Tujino K; Tanizaki S; Iwahori K; Hirata H; Miki K; Yanagawa M; Takeuchi N; Takeda Y; Kida H; Kumanogoh A
    RMD Open; 2023 Jan; 9(1):. PubMed ID: 36690385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.
    Pugashetti JV; Adegunsoye A; Wu Z; Lee CT; Srikrishnan A; Ghodrati S; Vo V; Renzoni EA; Wells AU; Garcia CK; Chua F; Newton CA; Molyneaux PL; Oldham JM
    Am J Respir Crit Care Med; 2023 Jan; 207(1):69-76. PubMed ID: 35943866
    [No Abstract]   [Full Text] [Related]  

  • 17. Prevalence and prognosis of unclassifiable interstitial lung disease.
    Ryerson CJ; Urbania TH; Richeldi L; Mooney JJ; Lee JS; Jones KD; Elicker BM; Koth LL; King TE; Wolters PJ; Collard HR
    Eur Respir J; 2013 Sep; 42(3):750-7. PubMed ID: 23222877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.
    Brown KK; Inoue Y; Flaherty KR; Martinez FJ; Cottin V; Bonella F; Cerri S; Danoff SK; Jouneau S; Goeldner RG; Schmidt M; Stowasser S; Schlenker-Herceg R; Wells AU
    Respirology; 2022 Apr; 27(4):294-300. PubMed ID: 35224814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life prevalence of progressive fibrosing interstitial lung diseases.
    Gagliardi M; Berg DV; Heylen CE; Koenig S; Hoton D; Tamirou F; Pieters T; Ghaye B; Froidure A
    Sci Rep; 2021 Dec; 11(1):23988. PubMed ID: 34907290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
    Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
    Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.